Can lower T3 availability worsen lipid metabolism and raise atherosclerotic cardiovascular risk even with normal TSH?

Clinical and epidemiological research demonstrates a robust link between lower triiodothyronine (T3) availability—even when thyroid-stimulating hormone (TSH) is within the normal reference range—and worsened lipid metabolism and heightened atherosclerotic cardiovascular disease (ASCVD) risk.

Clinical and metabolic evidence

• Lipid Profile Impairments: Large cohort and Mendelian randomization studies consistently show that individuals with low-normal free T3 (FT3) levels or a low FT3 to free thyroxine (FT4) ratio display elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride levels. These lipid alterations occur even when TSH levels remain entirely normal, showing that standard thyroid screening can overlook tissue-level lipid-clearance deficits.
• Elevated Cardiovascular Risk: In the EPIPorto population cohort, euthyroid individuals in the lowest FT3/FT4 ratio quartile exhibited a 1.5- to 2-fold higher odds of being classified in a higher 10-year cardiovascular risk category, independent of traditional metabolic risk factors.
• Prognostic Impact in Vascular Disease: Among patients with established coronary artery disease or those undergoing percutaneous coronary intervention, a reduced FT3/FT4 ratio—reflecting impaired peripheral conversion of T4 to T3—independently predicts severe coronary stenosis, coronary microvascular dysfunction, and major adverse cardiac events (MACE), including cardiac death.

Mechanistic pathways of lipid regulation

• Hepatic Receptor Downregulation: Under normal conditions, T3 upregulates the transcription of sterol regulatory element-binding protein-2 (SREBP-2) and the LDL receptor (LDLR) in hepatocytes. Lower T3 availability directly downregulates these pathways, reducing hepatic LDLR density and impairing the clearance of circulating LDL-C.
• Impaired Lipase Activity and Bile Acid Synthesis: T3 signaling activates lipoprotein lipase, hepatic lipase, and cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme converting cholesterol into bile acids. A reduction in local T3 availability leads to diminished lipase and CYP7A1 activity, resulting in elevated triglycerides and accumulation of atherogenic lipoprotein remnants.

Bottom line

For an older adult, particularly a 61-year-old male, lower T3 availability—indicated by low-normal FT3 or a low FT3/FT4 ratio—is an independent marker of an atherogenic lipid profile and elevated ASCVD risk. Because this state commonly persists despite normal TSH levels, standard thyroid screenings may fail to capture these underlying lipid clearance and vascular risks.